Ligand Pharmaceuticals Incorporated (LGND)
LGND Stock Price Chart
Explore Ligand Pharmaceuticals Incorporated interactive price chart. Choose custom timeframes to analyze LGND price movements and trends.
LGND Company Profile
Discover essential business fundamentals and corporate details for Ligand Pharmaceuticals Incorporated (LGND) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Nov 1992
Employees
68.00
Website
https://www.ligand.comCEO
Todd C. Davis
Description
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
LGND Financial Timeline
Browse a chronological timeline of Ligand Pharmaceuticals Incorporated corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is $1.93, while revenue estimate is $61.70m.
Earnings released on 14 May 2026
EPS came in at $1.63 falling short of the estimated $1.84 by -11.41%, while revenue for the quarter reached $51.72m , missing expectations by -12.48%.
Earnings released on 26 Feb 2026
EPS came in at $2.02 surpassing the estimated $1.46 by +38.36%, while revenue for the quarter reached $59.67m , beating expectations by +7.33%.
Earnings released on 6 Nov 2025
EPS came in at $3.09 surpassing the estimated $1.97 by +56.85%, while revenue for the quarter reached $115.46m , beating expectations by +107.71%.
Earnings released on 7 Aug 2025
EPS came in at $1.60 surpassing the estimated $1.54 by +3.90%, while revenue for the quarter reached $47.63m , missing expectations by -9.85%.
Earnings released on 8 May 2025
EPS came in at $1.33 surpassing the estimated $1.30 by +2.31%, while revenue for the quarter reached $45.33m , beating expectations by +2.32%.
Earnings released on 27 Feb 2025
EPS came in at -$1.64 falling short of the estimated $1.37 by -219.71%, while revenue for the quarter reached $42.81m , beating expectations by +21.26%.
Earnings released on 7 Nov 2024
EPS came in at -$0.39 falling short of the estimated $0.75 by -152.00%, while revenue for the quarter reached $51.81m , beating expectations by +32.81%.
Earnings released on 6 Aug 2024
EPS came in at $1.40 surpassing the estimated $1.10 by +27.27%, while revenue for the quarter reached $41.53m , beating expectations by +26.39%.
Earnings released on 7 May 2024
EPS came in at $1.20 surpassing the estimated $1.13 by +6.19%, while revenue for the quarter reached $30.98m , beating expectations by +10.95%.
Earnings released on 27 Feb 2024
EPS came in at $1.05 surpassing the estimated $0.58 by +81.03%, while revenue for the quarter reached $28.10m , beating expectations by +9.26%.
Earnings released on 8 Nov 2023
EPS came in at $1.02 surpassing the estimated $0.68 by +50.00%, while revenue for the quarter reached $32.87m , beating expectations by +20.88%.
Earnings released on 8 Aug 2023
EPS came in at $1.42 surpassing the estimated $0.76 by +86.84%, while revenue for the quarter reached $26.37m , beating expectations by +2.47%.
Earnings released on 4 May 2023
EPS came in at $2.28 surpassing the estimated $0.89 by +156.18%, while revenue for the quarter reached $43.98m , beating expectations by +29.20%.
Earnings released on 22 Feb 2023
EPS came in at $1.36 surpassing the estimated $1.23 by +10.57%, while revenue for the quarter reached $50.38m , beating expectations by +14.27%.
Earnings released on 7 Nov 2022
EPS came in at $0.41 falling short of the estimated $0.45 by -8.89%, while revenue for the quarter reached $66.09m , beating expectations by +72.45%.
Stock split effective on 2 Nov 2022
Shares were split 1603 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Aug 2022
EPS came in at $0.34 falling short of the estimated $0.54 by -37.04%, while revenue for the quarter reached $57.42m , beating expectations by +52.16%.
Earnings released on 4 May 2022
EPS came in at $0.58 falling short of the estimated $0.61 by -4.92%, while revenue for the quarter reached $45.69m , beating expectations by +33.57%.
Earnings released on 17 Feb 2022
EPS came in at $1.80 surpassing the estimated $1.38 by +30.43%, while revenue for the quarter reached $72.47m , beating expectations by +11.35%.
Earnings released on 9 Nov 2021
EPS came in at $1.58 surpassing the estimated $1.02 by +54.90%, while revenue for the quarter reached $64.84m , beating expectations by +21.71%.
Earnings released on 29 Jul 2021
EPS came in at $1.63 surpassing the estimated $1.36 by +19.85%, while revenue for the quarter reached $84.68m , beating expectations by +20.12%.
LGND Stock Performance
Access detailed LGND performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
